MDM2, MDMX and p53 in oncogenesis and cancer therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23303139.
- Also identified by DOI 10.1038/nrc3430 and PMC identifier 4161369.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour suppressor. However, the MDM proteins modulate and respond to many other signalling networks in which they are embedded. Recent mechanistic studies and animal models have demonstrated how functional interactions in these networks are crucial for maintaining normal tissue homeostasis, and for determining responses to oncogenic and therapeutic challenges. This Review highlights the progress made and pitfalls encountered as the field continues to search for MDM-targeted antitumour agents.
Medical subject headings
- Cell Transformation, Neoplastic
- Neoplasms
- Proto-Oncogene Proteins c-mdm2
- Tumor Suppressor Protein p53